Adrenoleukodystrophy Pipeline Review, H2 2020 Edition – Therapeutics Development and Assessment, Drug Profiles, Dormant Projects, Product Development Milestones, Competitive Landscape – ResearchAndMarkets.com

Adrenoleukodystrophy Pipeline Review, H2 2020 Edition – Therapeutics Development and Assessment, Drug Profiles, Dormant Projects, Product Development Milestones, Competitive Landscape – ResearchAndMarkets.com




Adrenoleukodystrophy Pipeline Review, H2 2020 Edition – Therapeutics Development and Assessment, Drug Profiles, Dormant Projects, Product Development Milestones, Competitive Landscape – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Adrenoleukodystrophy – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Adrenoleukodystrophy – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Introduction

Adrenoleukodystrophy – Overview

Adrenoleukodystrophy – Therapeutics Development

Adrenoleukodystrophy – Therapeutics Assessment

Adrenoleukodystrophy – Companies Involved in Therapeutics Development

Adrenoleukodystrophy – Drug Profiles

Adrenoleukodystrophy – Dormant Projects

Adrenoleukodystrophy – Discontinued Products

Adrenoleukodystrophy – Product Development Milestones

Appendix

Companies Mentioned

  • Applied Genetic Technologies Corp
  • Ashvattha Therapeutics LLC
  • bluebird bio Inc
  • Magenta Therapeutics Inc
  • MedDay SA
  • Minoryx Therapeutics sl
  • NeuroVia Inc
  • Orpheris Inc
  • Poxel SA
  • Recursion Pharmaceuticals Inc
  • SwanBio Therapeutics Ltd
  • Viking Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p8jg55

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900